NNVC — NanoViricides, Inc.
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: AMEX
- Employees: 7
- Website: https://www.nanoviricides.com
Latest SEC filings for NNVC
- 424B5 — 2026-10-21
- 424B3 — 2026-09-03
- EFFECT — 2026-09-01
- S-3 — 2026-08-21
- S-3 — 2026-08-21
- 8-K — 2026-07-30
- 424B5 — 2026-07-27
- 424B5 — 2026-07-27
- 424B5 — 2026-07-27
- 424B5 — 2026-07-27
Latest NNVC news
- — Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides (accessnewswire.com)
- — NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 (accessnewswire.com)
- — NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives (accessnewswire.com)
- — NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials (accessnewswire.com)
- — Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides (accessnewswire.com)
Educational tool only — not investment advice.